Checkpoint inhibitors such as antibodies against cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and programmed cell death 1 (anti-PD-1), etc, have been shown to be partially effective against several malignant tumors [6, 7] including HCC [8]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.